Lantern Pharma bags FDA orphan drug status for LP-184 in pancreatic cancer
Lantern Pharma has secured orphan drug designation for its small molecule drug candidate LP-184 from the US Food and Drug Administration (FDA) for the treatment of pancreatic cancer. According to the Texas-based clinical stage biopharma company, LP-184 is a next generation alkylating agent that selectively damages DNA in cancer cells that over-express certain biomarkers or […]